Alice T Shaw Luc Friboulet Ignaty Leshchiner Justin F Gainor Simon Bergqvist Alexei Brooun Benjamin J Burke Ya-Li Deng Wei Liu Leila Dardaei Rosa L Frias Kate R Schultz Jennifer Logan Leonard P James Tod Smeal Sergei Timofeevski Ryohei Katayama A John Iafrate Long Le Michele McTigue Gad Getz Ted W Johnson Jeffrey A Engelman
10.1056/NEJMoa1508887
N Engl J Med
2016 Jan 7;374(1):54-61.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/26698910/
Carcinoma, Non-Small-Cell Lung / drug therapy Drug Resistance, Neoplasm / genetics Lactams, Macrocyclic / therapeutic use Lung Neoplasms / drug therapy Mutation Protein Kinase Inhibitors / therapeutic use Pyrazoles / therapeutic use Pyridines / therapeutic use Receptor Protein-Tyrosine Kinases / genetics
Carcinoma, Non-Small-Cell Lung / drug therapy Drug Resistance, Neoplasm / genetics Lactams, Macrocyclic / therapeutic use Lung Neoplasms / drug therapy Mutation Protein Kinase Inhibitors / therapeutic use Pyrazoles / therapeutic use Pyridines / therapeutic use Receptor Protein-Tyrosine Kinases / genetics Case Reports Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Aminopyridines Anaplastic Lymphoma Kinase Binding Sites Carcinoma, Non-Small-Cell Lung / genetics Carcinoma, Non-Small-Cell Lung / secondary Crizotinib Female Humans Lactams Liver Failure / etiology Liver Neoplasms / secondary Lung Neoplasms / genetics Middle Aged Molecular Structure Pyrimidines / therapeutic use Receptor Protein-Tyrosine Kinases / antagonists & inhibitors Sulfones / therapeutic use Aminopyridines Lactams Lactams, Macrocyclic Protein Kinase Inhibitors Pyrazoles Pyridines Pyrimidines Sulfones Crizotinib ALK protein, human Anaplastic Lymphoma Kinase Receptor Protein-Tyrosine Kinases ceritinib lorlatinib
PMC4773904
26698910
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
2016